Compass Group PLC Sponsored ADR (CMPGY)
Compass Diversified Q2 Earnings Call Highlights
Compass Diversified NYSE: CODI reported second-quarter results marked by double-digit growth in subsidiary adjusted EBITDA, improved operating cash flow and lower debt following the sale of Sterno's food service business, while maintaining its full-year 2026 outlook.
Compass Minerals International Q3 Earnings Call Highlights
Compass Minerals International NYSE: CMP reported fiscal third-quarter adjusted EBITDA of $39.9 million, compared with $41 million a year earlier, as stronger pricing in its salt and plant nutrition businesses was offset by lower highway de-icing volumes and higher production and distribution costs in salt.
Despite Fast-paced Momentum, Compass (COMP) Is Still a Bargain Stock
Compass (COMP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Compass Pathways Q2 Earnings Call Highlights
Compass Pathways NASDAQ: CMPS said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials.
Compass Q2 Earnings Call Highlights
Compass NYSE: COMP reported record second-quarter revenue and adjusted EBITDA, with results exceeding its guidance range as the company continued integrating the Anywhere businesses acquired earlier this year.
Compass, Inc. (COMP) Q2 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q2 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q2 Earnings Match Estimates
Compass, Inc. (COMP) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly's move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate.
Compass Group PLC (CMPGY) Q3 2026 Sales/Trading Call Transcript
Compass Group PLC (CMPGY) Q3 2026 Sales/Trading Call Transcript
Compass Group Q3 Earnings Call Highlights
Compass Group LON: CPG reported another strong quarter in its third-quarter trading update, with Group Chief Executive Officer Dominic Blakemore saying the company delivered organic revenue growth of more than 7% and maintained client retention at 96%.
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company's psychological support approach from psychotherapy, Jefferies analysts have highlighted. In a note reviewing a post-hoc analysis of Compass Pathways (NASDAQ:CMPS)' completed Phase II open-label trial of COMP360 in post-traumatic stress disorder (PTSD), Jefferies wrote that the study provided further detail on how the company's treatment model separates monitoring and support during dosing sessions from traditional talk therapy.
Top FTSE 100 Index shares to watch next week: Airtel, BT Group, Compass Group
The FTSE 100 Index has remained in a narrow range this week as traders reacted to the rising tensions between the US and Iran. It also wavered as the United States earnings season started, with big names like JPMorgan, Goldman Sachs, and Netflix releasing their earnings.
